

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L3	4	human adj chaperone adj protein	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 10:02			0
2	BRS	L5	2	polynucleotide same 3	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:57			0
3	BRS	L6	0	cell same transform\$2 same 5	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:58			0
4	BRS	L7	212	yue adj henry.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:58			0
5	BRS	L8	406	bandman adj olga.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:59			0
6	BRS	L9	1126	tang adj y.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:59			0
7	BRS	L10	184	baughn adj maria.h.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 09:59			0
8	BRS	L11	51	azimzai adj yalda.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 10:00			0
9	BRS	L12	52	lu adj dyung.in.	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 10:01			0
10	BRS	L13	2	(7 or 8 or 9 or 10 or 11 or 12) and 3	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 10:01			0
11	BRS	L14	0	HCPN-11	USPAT; US-PGPUB; EPO; JPO;	2004/01/02 10:02			0

LE 'MEDLINE' ENTERED AT 10:05:09 ON 02 JAN 2004
LE 'CAPLUS' ENTERED AT 10:05:09 ON 02 JAN 2004
E IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
EASE SEE "HELP USAGETERMS" FOR DETAILS.
PYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
LE 'BIOSIS' ENTERED AT 10:05:09 ON 02 JAN 2004
PYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)
LE 'EMBASE' ENTERED AT 10:05:09 ON 02 JAN 2004
PYRIGHT (C) 2004 Elsevier Inc. All rights reserved.
LE 'SCISEARCH' ENTERED AT 10:05:09 ON 02 JAN 2004
PYRIGHT 2004 THOMSON ISI
LE 'AGRICOLA' ENTERED AT 10:05:09 ON 02 JAN 2004

s human chaperone protein
8 HUMAN CHAPERONE PROTEIN

s HCPN-11
0 HCPN-11

duplicate remove l1
PLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
EP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L1
4 DUPLICATE REMOVE L1 (4 DUPLICATES REMOVED)

d l3 1-4 ibib abs

ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
CESSION NUMBER: 2001:101182 CAPLUS
OCUMENT NUMBER: 134:159191
ITLE: ***Human*** ***chaperone*** ***protein***
(HCPN) sequence homologs, their sequences, cDNA
encoding them, and their biological and therapeutic
uses
VENTOR(S): Yue, Henry; Bandman, Olga; Tang, Y. Tom; Baughn,
Mariah R.; Azimzai, Yalda; Lu, Dyung Aina M.
ATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
OURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
OCUMENT TYPE: Patent
ANGUAGE: English
AMILY ACC. NUM. COUNT: 1
ATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009178	A2	20010208	WO 2000-US21313	20000803
WO 2001009178	A3	20010927		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1203015	A2	20020508	EP 2000-952500	20000803
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003529327	T2	20031007	JP 2001-513984	20000803
PRIORITY APPLN. INFO.:			US 1999-146908P	P 19990803
			US 1999-160924P	P 19991022
			WO 2000-US21313	W 20000803

B The invention provides eleven human proteins, which are believed to be chaperone proteins (HCPN) based on sequence homol. to known heat-shock, chaperone and DnaJ proteins. The invention also provides cDNA mols. encoding the HCPN sequence homologs. The invention further provides a DNA construct contg. a promoter linked to said HCPN cDNA mols., and a cell and/or organism transformed for with said DNA construct, which are used for recombinant prodn. of HCPN. Still further the invention provides: (1) a pharmaceutical compn. contg. said HCPN; (2) antibodies specific for

HCPN; (3) primers and/or probes specific for polynucleotides encoding HCPN; (4) RNA equiv. of HCPN cDNA mols.; and (5) mol. genetic techniques, such as polymerase chain reaction (PCR) and/or nucleic acid hybridization for detecting polynucleotides encoding HCPN using said primers and probes. Finally the invention provides: (1) screening methods for agonists and/or antagonists of HCPN, and (2) use of identified agonists and/or antagonists in treating a disease or disorder assocd. with an imbalance of functional HCPN. The cDNA sequences as well as the corresponding amino acid sequences of the HCPN sequence homologs are provided. The invention presented information on the cloning of each cDNA mol., including what tissues were utilized in constructing the cDNA libraries. In addn., the invention presented information on the structure and potential function of the HCPN including: (1) potential phosphorylation and glycosylation sites; (2) signature sequences and protein motifs; and (3) proteins from other organisms that show homol. Finally, the invention presented information on the tissue expression of the cDNA clones as detd. by Northern blot, and diseases and/or disorders assocd. with these tissues.

ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
 CESSION NUMBER: 2000:210378 CAPLUS
 DOCUMENT NUMBER: 132:247181
 TITLE: ***Human*** ***chaperone*** ***proteins***
 and their encoding nucleic acids
 INVENTOR(S): Tang, Y. Tom; Hillman, Jennifer L.; Yue, Henry;
 Patterson, Chandra; Baughn, Mariah R.; Batra, Sajeev
 PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017358	A2	20000330	WO 1999-US22027	19990922
WO 2000017358	A3	20000720		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2343718	AA	20000330	CA 1999-2343718	19990922
AU 9960582	A1	20000410	AU 1999-60582	19990922
EP 1115864	A2	20010718	EP 1999-969442	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:
 US 1998-158642 A 19980922
 US 1998-172221P P 19980922
 US 1999-233291 A 19990119
 US 1999-172232P P 19990419
 US 1999-294698 A 19990419
 WO 1999-US22027 W 19990922

B The invention provides 6 ***human*** ***chaperone***
 proteins (HCHP) and polynucleotides which identify and encode HCHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides the use of these sequences in the diagnosis, treatment, and prevention of neurodegenerative, metabolic, developmental, autoimmune-inflammatory disorders and cell proliferative disorders including cancer assocd. with expression of HCHP.

ANSWER 3 OF 4 MEDLINE on STN DUPLICATE 1
 CESSION NUMBER: 1999024006 MEDLINE
 DOCUMENT NUMBER: 99024006 PubMed ID: 9804845
 TITLE: Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication.
 AUTHOR: Liu J S; Kuo S R; Makhov A M; Cyr D M; Griffith J D; Broker T R; Chow L T
 CORPORATE SOURCE: Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama 35294-0005 USA

TRACT NUMBER: CA19014 (NCI)

CA36200 (NCI)

GM31819 (NIGMS)

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 Nov 13) 273 (46)
30704-12.
Journal code: 2985121R. ISSN: 0021-9258.

OB. COUNTRY: United States

OCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199812

ENTRY DATE: Entered STN: 19990115

Last Updated on STN: 19990115

Entered Medline: 19981208

Human papillomavirus replication initiator, the E1 helicase, binds weakly to the origin of DNA replication. Purified ***human***
chaperone ***proteins*** Hsp70 and Hsp40 (HDJ-1 and HDJ-2) independently and additively enhanced E1 binding to the origin. The interaction between E1 and Hsp70 was transient and required ATP hydrolysis, whereas Hsp40 bound to E1 directly and remained in the complex. A peptide of 20 residues spanning the HPD loop and helix II of the J domain of YDJ-1 also stimulated E1 binding to the origin, alone or in combination with Hsp70 or Hsp40. A mutated peptide (H34Q) had a reduced activity, while an adjacent or an overlapping peptide had no effect. Neither Hsp70 nor the J peptide altered the E1/DNA ratio in the complex. Electron microscopy showed that E1 mainly bound to DNA as a hexamer. In the presence of Hsp40, E1 primarily bound to DNA as a dihexamer. Preincubation of chaperones with viral E1 and template shortened the lag time and increased replication in a cell-free system. Since two helicases are essential for bidirectional replication of human papillomavirus DNA, these results demonstrate that, as in prokaryotes, chaperones play an important role in the assembly of preinitiation complexes on the origin.

ANSWER 4 OF 4 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

CESSION NUMBER: 94:778629 SCISEARCH

HE GENUINE ARTICLE: PV929

ITLE: HIV RELIES ON ***HUMAN*** ***CHAPERONE***

PROTEIN TO REPRODUCE

UTHOR: BROWN P (Reprint)

OURCE: NEW SCIENTIST, (03 DEC 1994) Vol. 144, No. 1954, pp. 20.

ISSN: 0262-4079.

OCUMENT TYPE: Editorial; Journal

ILE SEGMENT: AGRI; ENGI

LANGUAGE: ENGLISH

EFERENCE COUNT: No References

> d his

(FILE 'HOME' ENTERED AT 10:04:39 ON 02 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
10:05:09 ON 02 JAN 2004

1 8 S HUMAN CHAPERONE PROTEIN
2 0 S HCPN-11
3 4 DUPLICATE REMOVE L1 (4 DUPLICATES REMOVED)

> s polynucleotide (p) l3

ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'UCLEOTIDE (P) L20'
ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'UCLEOTIDE (P) L22'
ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'UCLEOTIDE (P) L26'
4 0 POLYNUCLEOTIDE (P) L3

> s cell (p) transform? (p) l3

ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'RANSFORM? (P) L33'
ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'RANSFORM? (P) L35'
ROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
IELD CODE - 'AND' OPERATOR ASSUMED 'RANSFORM? (P) L39'
5 1 CELL (P) TRANSFORM? (P) L3

d 15 1 ibib abs

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
SESSION NUMBER: 2001:101182 CAPLUS
DOCUMENT NUMBER: 134:159191
TITLE: Human chaperone protein (HCPN) sequence homologs,
their sequences, cDNA encoding them, and their
biological and therapeutic uses
INVENTOR(S): Yue, Henry; Bandman, Olga; Tang, Y. Tom; Baughn,
Mariah R.; Azimzai, Yalda; Lu, Dyung Aina M.
PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009178	A2	20010208	WO 2000-US21313	20000803
WO 2001009178	A3	20010927		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1203015	A2	20020508	EP 2000-952500	20000803
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003529327	T2	20031007	JP 2001-513984	20000803
PRIORITY APPLN. INFO.:			US 1999-146908P	P 19990803
			US 1999-160924P	P 19991022
			WO 2000-US21313	W 20000803

3 The invention provides eleven human proteins, which are believed to be chaperone proteins (HCPN) based on sequence homol. to known heat-shock, chaperone and DnaJ proteins. The invention also provides cDNA mols. encoding the HCPN sequence homologs. The invention further provides a DNA construct contg. a promoter linked to said HCPN cDNA mols., and a cell and/or organism transformed for with said DNA construct, which are used for recombinant prodn. of HCPN. Still further the invention provides: (1) a pharmaceutical compn. contg. said HCPN; (2) antibodies specific for HCPN; (3) primers and/or probes specific for polynucleotides encoding HCPN; (4) RNA equiv. of HCPN cDNA mols.; and (5) mol. genetic techniques, such as polymerase chain reaction (PCR) and/or nucleic acid hybridization for detecting polynucleotides encoding HCPN using said primers and probes. Finally the invention provides: (1) screening methods for agonists and/or antagonists of HCPN, and (2) use of identified agonists and/or antagonists in treating a disease or disorder assocd. with an imbalance of functional HCPN. The cDNA sequences as well as the corresponding amino acid sequences of the HCPN sequence homologs are provided. The invention presented information on the cloning of each cDNA mol., including what tissues were utilized in constructing the cDNA libraries. In addn., the invention presented information on the structure and potential function of the HCPN including: (1) potential phosphorylation and glycosylation sites; (2) signature sequences and protein motifs; and (3) proteins from other organisms that show homol. Finally, the invention presented information on the tissue expression of the cDNA clones as detd. by Northern blot, and diseases and/or disorders assocd. with these tissues.

> s yue henry/au
6 411 YUE HENRY/AU

> s bandman olga/au
7 356 BANDMAN OLGA/AU

> s tang y?/au
8 11140 TANG Y?/AU

> s baughn mariah/au
9 16 BAUGHN MARIAH/AU

10 146 AZIMZAI YALDA/AU
 > s lu dyung/au
 L1 0 LU DYUNG/AU
 > s (16 or 17 or 18 or 19 or 110)
 L2 11546 (L6 OR L7 OR L8 OR L9 OR L10)
 > s 112 and 11
 L3 2 L12 AND L1
 > duplicate remove 113
 PROCESSING COMPLETED FOR L13
 L4 2 DUPLICATE REMOVE L13 (0 DUPLICATES REMOVED)
 > d 114 1-2 ibib abs

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 CESSION NUMBER: 2001:101182 CAPLUS
 DOCUMENT NUMBER: 134:159191
 TITLE: ***Human*** ***chaperone*** ***protein***
 (HCPN) sequence homologs, their sequences, cDNA
 encoding them, and their biological and therapeutic
 uses
 INVENTOR(S): ***Yue, Henry*** ; ***Bandman, Olga*** ;
 Tang, Y. Tom ; Baughn, Mariah R.; ***Azimzai,***
 Yalda ; Lu, Dyung Aina M.
 PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009178	A2	20010208	WO 2000-US21313	20000803
WO 2001009178	A3	20010927		
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG		
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1203015	A2	20020508	EP 2000-952500	20000803
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL		
JP 2003529327	T2	20031007	JP 2001-513984	20000803
PRIORITY APPLN. INFO.:			US 1999-146908P	P 19990803
			US 1999-160924P	P 19991022
			WO 2000-US21313	W 20000803

B The invention provides eleven human proteins, which are believed to be chaperone proteins (HCPN) based on sequence homol. to known heat-shock, chaperone and DnaJ proteins. The invention also provides cDNA mols. encoding the HCPN sequence homologs. The invention further provides a DNA construct contg. a promoter linked to said HCPN cDNA mols., and a cell and/or organism transformed for with said DNA construct, which are used for recombinant prodn. of HCPN. Still further the invention provides: (1) a pharmaceutical compn. contg. said HCPN; (2) antibodies specific for HCPN; (3) primers and/or probes specific for polynucleotides encoding HCPN; (4) RNA equiv. of HCPN cDNA mols.; and (5) mol. genetic techniques, such as polymerase chain reaction (PCR) and/or nucleic acid hybridization for detecting polynucleotides encoding HCPN using said primers and probes. Finally the invention provides: (1) screening methods for agonists and/or antagonists of HCPN, and (2) use of identified agonists and/or antagonists in treating a disease or disorder assocd. with an imbalance of functional HCPN. The cDNA sequences as well as the corresponding amino acid sequences of the HCPN sequence homologs are provided. The invention presented information on the cloning of each cDNA mol., including what tissues were utilized in constructing the cDNA libraries. In addn., the invention presented information on the structure and potential function of the HCPN including: (1) potential phosphorylation and glycosylation sites; (2) signature sequences and protein motifs; and (3) proteins from other organisms that show homol. Finally, the invention presented information

on the tissue expression of the cDNA clones as detd. by Northern blot, and diseases and/or disorders assocd. with these tissues.

4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
SESSION NUMBER: 2000:210378 CAPLUS
DOCUMENT NUMBER: 132:247181
TITLE: ***Human*** ***chaperone*** ***proteins***
and their encoding nucleic acids
INVENTOR(S): ***Tang, Y. Tom*** ; Hillman, Jennifer L.;
Yue, Henry ; Patterson, Chandra; Baughn, Mariah
R.; Batra, Sajeev
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017358	A2	20000330	WO 1999-US22027	19990922
WO 2000017358	A3	20000720		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2343718	AA	20000330	CA 1999-2343718	19990922
AU 9960582	A1	20000410	AU 1999-60582	19990922
EP 1115864	A2	20010718	EP 1999-969442	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:				
US 1998-158642 A 19980922				
US 1998-172221P P 19980922				
US 1999-233291 A 19990119				
US 1999-172232P P 19990419				
US 1999-294698 A 19990419				
WO 1999-US22027 W 19990922				

3 The invention provides 6 ***human*** ***chaperone***
proteins (HCHP) and polynucleotides which identify and encode HCHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides the use of these sequences in the diagnosis, treatment, and prevention of neurodegenerative, metabolic, developmental, autoimmune-inflammatory disorders and cell proliferative disorders including cancer assocd. with expression of HCHP.

> d his

(FILE 'HOME' ENTERED AT 10:04:39 ON 02 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 10:05:09 ON 02 JAN 2004

1 8 S HUMAN CHAPERONE PROTEIN
2 0 S HCPN-11
3 4 DUPLICATE REMOVE L1 (4 DUPLICATES REMOVED)
4 0 S POLYNUCLEOTIDE (P) L3
5 1 S CELL (P) TRANSFORM? (P) L3
6 411 S YUE HENRY/AU
7 356 S BANDMAN OLGA/AU
8 11140 S TANG Y?/AU
9 16 S BAUGHN MARIAH/AU
10 146 S AZIMZAI YALDA/AU
11 0 S LU DYUNG/AU
12 11546 S (L6 OR L7 OR L8 OR L9 OR L10)
13 2 S L12 AND L1
14 2 DUPLICATE REMOVE L13 (0 DUPLICATES REMOVED)

> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSTON